Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Atezolizumab + Tiragolumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
Tiragolumab | RO7092284|RG6058|MTIG7192A | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 | Tiragolumab (MTIG7192A) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (PMID: 29991503, PMID: 32576590). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05798663 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | Recruiting | USA | 0 |
NCT05681039 | Phase II | Atezolizumab + Carboplatin + Tiragolumab Atezolizumab + Cisplatin + Tiragolumab Atezolizumab + Tiragolumab | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | Recruiting | USA | 0 |
NCT06175390 | Phase II | Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Carboplatin + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Tiragolumab | Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE) | Recruiting | FRA | 0 |
NCT03563716 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | ESP | 3 |
NCT05715281 | Phase II | Atezolizumab + Tiragolumab | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | Recruiting | USA | 0 |
NCT05483400 | Phase II | Atezolizumab + Tiragolumab | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) | Recruiting | NLD | 0 |
NCT05661578 | Phase II | Atezolizumab + Tiragolumab | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11) | Recruiting | USA | TUR | HRV | GRC | ESP | CYP | CAN | 6 |
NCT04513925 | Phase III | Atezolizumab + Tiragolumab Durvalumab | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT04294810 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) | Active, not recruiting | USA | TUR | POL | NLD | ITA | HUN | GRC | ESP | DNK | DEU | CHE | BRA | AUT | AUS | 10 |
NCT04543617 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | ARG | 11 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Completed | USA | 0 |
NCT06267001 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15) | Active, not recruiting | USA | TUR | SVK | POL | ITA | FRA | ESP | BRA | AUS | ARG | 6 |
NCT05661188 | Phase II | Atezolizumab + Tiragolumab Cisplatin + Fluorouracil | Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS) | Recruiting | ESP | 0 |
NCT02794571 | Phase I | Atezolizumab + Tiragolumab Tiragolumab | Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | FRA | ESP | CAN | AUS | 2 |
NCT05459129 | Phase Ib/II | Atezolizumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | Completed | USA | ISR | FRA | AUS | 1 |
NCT06603818 | Phase II | Atezolizumab + Tiragolumab | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Not yet recruiting | USA | 0 |
NCT06003621 | Phase II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP) | Recruiting | AUS | 0 |
NCT03281369 | Phase Ib/II | Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Active, not recruiting | USA | ISR | GBR | ESP | AUS | 2 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Recruiting | FRA | 0 |
NCT05060003 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | Terminated | USA | 0 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04300647 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 8 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT04832854 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | Active, not recruiting | USA | ESP | CHE | AUS | 1 |
NCT04665843 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) | Active, not recruiting | USA | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE | 3 |
NCT05825625 | Phase II | Atezolizumab + Tiragolumab | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | Recruiting | DEU | 0 |
NCT06342037 | Phase II | Atezolizumab + Tiragolumab Ipilimumab + Tiragolumab Atezolizumab + Ipilimumab + Tiragolumab | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3) | Recruiting | NLD | 0 |
NCT05116202 | Phase Ib/II | RO7247669 Atezolizumab + Tiragolumab Ipilimumab + Nivolumab RO7247669 + Tiragolumab | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | Completed | USA | NLD | ITA | FRA | ESP | AUS | 0 |